​

Insulet (PODD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PODD Stock Forecast

Insulet stock forecast is as follows: an average price target of $268.00 (represents a 1.77% upside from PODD’s last price of $263.35) and a rating consensus of 'Buy', based on 17 wall street analysts offering a 1-year stock forecast.

PODD Price Target

The average price target for Insulet (PODD) is $268.00 based on 1-year price targets from 17 Wall Street analysts in the past 3 months, with a price target range of $300.00 to $233.00. This represents a potential 1.77% upside from PODD's last price of $263.35.

PODD Analyst Ratings

Buy

According to 17 Wall Street analysts, Insulet's rating consensus is 'Buy'. The analyst rating breakdown for PODD stock is 0 'Strong Buy' (0.00%), 15 'Buy' (88.24%), 2 'Hold' (11.76%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Insulet Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 08, 2024Marie ThibaultBTIG$270.00$268.960.39%2.53%
Nov 05, 2024Lee HambrightBernstein$300.00$241.3224.32%13.92%
Oct 14, 2024Jayson BedfordRaymond James$260.00$231.6112.26%-1.27%
Sep 17, 2024Matt O'BrienPiper Sandler$285.00$233.8921.85%8.22%
Aug 27, 2024Matt O'BrienPiper Sandler$230.00$193.5118.85%-12.66%
Aug 27, 2024Steven LichtmanOppenheimer$233.00$193.5420.39%-11.52%
Aug 27, 2024Matthew TaylorJefferies$260.00$193.5434.34%-1.27%
Aug 09, 2024Marie ThibaultBTIG$250.00$199.7925.13%-5.07%
May 13, 2024Matt MiksicBarclays$200.00$165.9020.55%-24.06%
May 07, 2024Mike PolarkWolfe Research$200.00$176.4013.38%-24.06%
Mar 21, 2024Kyle RoseCanaccord Genuity$226.00$166.6435.62%-14.18%
Jan 06, 2023Morgan Stanley$320.00$295.008.47%21.51%
Nov 03, 2022Matt O'BrienPiper Sandler$340.00$255.3533.15%29.11%
Oct 17, 2022Cecilia FurlongMorgan Stanley$273.00$224.1621.79%3.66%
Aug 23, 2022Jayson BedfordRaymond James$280.00$260.037.68%6.32%
Mar 03, 2022Travis SteedBank of America Securities$300.00$265.3913.04%13.92%
Feb 02, 2022Matthew TaylorUBS$325.00$253.1928.36%23.41%
Jan 31, 2022Steven LichtmanOppenheimer$275.00$248.0010.89%4.42%
Dec 06, 2021Kyle RoseCanaccord Genuity$330.00$259.1427.34%25.31%
Nov 08, 2021Ravi MisraBerenberg Bank$295.00$313.47-5.89%12.02%
Nov 05, 2021Joanne WuenschCitigroup$350.00$308.0013.64%32.90%
Oct 12, 2021Raj DenhoyJefferies$340.00$297.5114.28%29.11%
Jul 21, 2021Josh JenningsCowen & Co.$310.00$271.4814.19%17.71%
May 07, 2021JP McKimThrivent$250.00$234.196.75%-5.07%

The latest Insulet stock forecast, released on Nov 08, 2024 by Marie Thibault from BTIG, set a price target of $270.00, which represents a 0.39% increase from the stock price at the time of the forecast ($268.96), and a 2.53% increase from PODD last price ($263.35).

Insulet Price Target by Period

1M3M12M
# Anlaysts-311
Avg Price Target-$276.67$246.73
Last Closing Price$263.35$263.35$263.35
Upside/Downside-100.00%5.06%-6.31%

In the current month, the average price target of Insulet stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Insulet's last price of $263.35. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Dec 11, 2024CitigroupBuyBuyHold
Dec 11, 2024CitigroupNeutralNeutralHold
Nov 05, 2024BernsteinOutperformInitialise
Oct 14, 2024William BlairBuyBuyHold
Oct 14, 2024Raymond JamesOutperformOutperformHold
Sep 17, 2024Piper SandlerUnderperformUnderperformHold
Sep 17, 2024UBSBuyBuyHold
Sep 17, 2024Piper SandlerOverweightOverweightHold
Aug 27, 2024Piper SandlerOverweightOverweightHold
Aug 27, 2024OppenheimerOutperformOutperformHold
Aug 27, 2024JefferiesBuyBuyHold
Aug 21, 2024Cowen & Co.BuyBuyHold
Aug 12, 2024UBSBuyBuyHold
Aug 12, 2024BarclaysEqual-WeightEqual-WeightHold
Aug 11, 2024Wells FargoOverweightOverweightHold
Aug 09, 2024BTIGBuyBuyHold
Aug 09, 2024UBSNeutralNeutralHold
Jul 23, 2024Wolfe ResearchBuyBuyHold
Jun 10, 2024OTR GlobalMixedDowngrade
May 13, 2024BarclaysEqual-WeightEqual-WeightHold
May 10, 2024JefferiesBuyBuyHold
May 07, 2024Wolfe ResearchOutperformUpgrade
Dec 21, 2023Pivotal ResearchOutperformUpgrade
Dec 04, 2023Morgan StanleyEqual-WeightOverweightUpgrade
Oct 02, 2023JefferiesBuyUpgrade
Aug 24, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Aug 21, 2023HSBCNeutralDowngrade
Aug 17, 2023J.P. MorganOverweightOverweightHold
Jan 06, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Nov 04, 2022BTIGBuyBuyHold
Nov 03, 2022Piper SandlerNeutralOverweightUpgrade
Aug 23, 2022Raymond JamesOutperformOutperformHold
Aug 05, 2022Raymond JamesNeutralNeutralHold
Aug 05, 2022Piper SandlerNeutralNeutralHold
May 17, 2022CitigroupBuyBuyHold
Apr 25, 2022BTIGBuyUpgrade
Feb 25, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Feb 24, 2022Raymond JamesOutperformOutperformHold
Feb 24, 2022Piper SandlerNeutralNeutralHold
Mar 22, 2021Canaccord GenuityBuyUpgrade

Insulet's last stock rating was published by Citigroup on Dec 11, 2024. The company gave PODD a "Buy" rating, the same as its previous rate.

Insulet Financial Forecast

Insulet Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$432.70M$396.50M$358.10M$369.70M$340.80M$299.40M$295.40M$307.70M$275.60M$263.20M$252.30M$246.10M$234.00M$226.30M$198.00M$209.39M$192.12M
Avg Forecast$790.86M$729.96M$679.61M$641.08M$682.89M$627.08M$579.64M$543.80M$582.70M$519.51M$488.00M$424.05M$461.26M$414.32M$385.26M$330.91M$332.45M$312.11M$291.45M$288.02M$299.33M$272.62M$258.88M$247.53M$232.90M$221.72M$212.41M$189.44M$199.51M$179.49M
High Forecast$805.16M$743.16M$691.90M$652.66M$695.24M$638.42M$590.12M$554.41M$589.75M$519.87M$496.82M$424.05M$467.11M$419.27M$392.22M$336.89M$338.46M$312.11M$291.45M$288.02M$299.33M$272.62M$258.88M$247.53M$232.90M$221.72M$212.41M$189.44M$199.51M$179.49M
Low Forecast$773.21M$713.67M$664.44M$626.77M$667.65M$613.09M$566.70M$531.18M$570.06M$519.16M$477.11M$424.05M$456.38M$406.12M$376.66M$323.52M$325.03M$312.11M$291.45M$288.02M$299.33M$272.62M$258.88M$247.53M$232.90M$221.72M$212.41M$189.44M$199.51M$179.49M
# Analysts64464379137749178877127148915101599168
Surprise %-------------1.04%1.03%1.08%1.11%1.09%1.03%1.03%1.03%1.01%1.02%1.02%1.06%1.06%1.07%1.05%1.05%1.07%

Insulet's average Quarter revenue forecast for Dec 23 based on 9 analysts is $461.26M, with a low forecast of $456.38M, and a high forecast of $467.11M. PODD's average Quarter revenue forecast represents a 6.60% increase compared to the company's last Quarter revenue of $432.70M (Sep 23).

Insulet EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts64464379137749178877127148915101599168
EBITDA-------------$55.50M$31.10M$27.50M$25.00M$1.10M$-27.80M$38.20M$62.60M$45.20M$2.40M$25.90M$19.20M$35.50M$38.40M$17.20M$26.14M$17.56M
Avg Forecast$99.31M$91.67M$85.34M$80.50M$85.76M$78.75M$72.79M$68.29M$73.17M$65.24M$61.28M$61.46M$57.92M$52.03M$48.38M$55.87M$47.34M$24.90M$23.25M$50.79M$23.88M$21.75M$20.65M$46.62M$18.58M$20.00M$16.94M$15.11M$15.92M$14.32M
High Forecast$101.11M$93.32M$86.89M$81.96M$87.31M$80.17M$74.10M$69.62M$74.06M$65.28M$62.39M$73.75M$58.66M$52.65M$49.25M$67.04M$56.81M$24.90M$23.25M$60.95M$23.88M$21.75M$20.65M$55.94M$18.58M$24.00M$16.94M$15.11M$15.92M$14.32M
Low Forecast$97.10M$89.62M$83.44M$78.71M$83.84M$76.99M$71.16M$66.70M$71.59M$65.19M$59.91M$49.17M$57.31M$51.00M$47.30M$44.70M$37.87M$24.90M$23.25M$40.63M$23.88M$21.75M$20.65M$37.30M$18.58M$16.00M$16.94M$15.11M$15.92M$14.32M
Surprise %-------------1.07%0.64%0.49%0.53%0.04%-1.20%0.75%2.62%2.08%0.12%0.56%1.03%1.77%2.27%1.14%1.64%1.23%

9 analysts predict PODD's average Quarter EBITDA for Dec 23 to be $57.92M, with a high of $58.66M and a low of $57.31M. This is 4.37% upper than Insulet's previous annual EBITDA (Sep 23) of $55.50M.

Insulet Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts64464379137749178877127148915101599168
Net Income-------------$51.90M$27.30M$23.80M$17.00M$-5.20M$-35.00M$27.80M$29.20M$12.60M$-25.00M-$-17.10M$11.60M$14.40M$-2.10M$4.97M$852.00K
Avg Forecast$113.52M$98.77M$80.19M$73.43M$90.20M$78.06M$62.75M$56.70M$76.14M$57.51M$41.69M$32.54M$48.29M$29.80M$19.41M$29.58M$22.08M$11.23M$16.58M$26.90M$23.14M$18.31M$9.94M$5.35M$-2.94M$6.54M$155.06K$-406.80K$8.03M$2.55M
High Forecast$116.18M$101.09M$82.08M$75.16M$92.31M$79.89M$64.22M$67.47M$85.56M$57.78M$41.72M$39.05M$58.38M$40.98M$19.87M$35.50M$26.50M$11.23M$16.58M$32.27M$23.14M$18.31M$9.94M$5.35M$-2.94M$7.84M$155.06K$-406.80K$8.03M$2.55M
Low Forecast$110.22M$95.91M$77.87M$71.30M$87.58M$75.79M$60.93M$45.94M$66.71M$57.24M$41.66M$26.03M$38.92M$19.37M$18.85M$23.67M$17.67M$11.23M$16.58M$21.52M$23.14M$18.31M$9.94M$5.35M$-2.94M$5.23M$155.06K$-406.80K$8.03M$2.55M
Surprise %-------------1.74%1.41%0.80%0.77%-0.46%-2.11%1.03%1.26%0.69%-2.52%-5.81%1.77%92.87%5.16%0.62%0.33%

Insulet's average Quarter net income forecast for Dec 23 is $48.29M, with a range of $38.92M to $58.38M. PODD's average Quarter net income forecast represents a -6.96% decrease compared to the company's last Quarter net income of $51.90M (Sep 23).

Insulet SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts64464379137749178877127148915101599168
SG&A-------------$180.70M$178.70M$162.70M$144.30M$140.40M$174.40M$128.70M$121.70M$117.50M$116.30M$110.50M$130.10M$89.20M$80.80M$83.90M$81.28M$75.30M
Avg Forecast$338.37M$312.31M$290.77M$274.28M$292.18M$268.30M$248.00M$232.66M$249.31M$222.27M$208.79M$150.66M$197.35M$177.27M$164.83M$136.96M$92.04M$133.53M$124.70M$124.51M$128.07M$116.64M$110.76M$198.90M$99.64M$50.26M$90.88M$81.05M$85.36M$76.80M
High Forecast$344.49M$317.96M$296.03M$279.24M$297.46M$273.15M$252.48M$237.20M$252.33M$222.43M$212.56M$180.79M$199.85M$179.38M$167.81M$164.35M$110.44M$133.53M$124.70M$149.41M$128.07M$116.64M$110.76M$238.68M$99.64M$60.31M$90.88M$81.05M$85.36M$76.80M
Low Forecast$330.82M$305.34M$284.28M$268.16M$285.66M$262.31M$242.46M$227.26M$243.90M$222.12M$204.13M$120.53M$195.26M$173.76M$161.15M$109.57M$73.63M$133.53M$124.70M$99.61M$128.07M$116.64M$110.76M$159.12M$99.64M$40.21M$90.88M$81.05M$85.36M$76.80M
Surprise %-------------1.02%1.08%1.19%1.57%1.05%1.40%1.03%0.95%1.01%1.05%0.56%1.31%1.77%0.89%1.04%0.95%0.98%

Insulet's average Quarter SG&A projection for Dec 23 is $197.35M, based on 9 Wall Street analysts, with a range of $195.26M to $199.85M. The forecast indicates a 9.21% rise compared to PODD last annual SG&A of $180.70M (Sep 23).

Insulet EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts64464379137749178877127148915101599168
EPS-------------$0.74$0.39$0.34$0.25$-0.07$-0.50$0.40$0.42$0.18$-0.37-$-0.26$0.18$0.22$-0.03$0.08$0.01
Avg Forecast$1.54$1.34$1.08$0.99$1.22$1.06$0.85$0.77$1.03$0.78$0.56$0.40$0.65$0.40$0.26$0.11$0.22$0.15$0.22$0.23$0.31$0.25$0.13$0.07$-0.04$0.08-$-0.01$0.11$0.03
High Forecast$1.57$1.37$1.11$1.02$1.25$1.08$0.87$0.91$1.16$0.78$0.56$0.40$0.79$0.55$0.27$0.11$0.22$0.15$0.22$0.23$0.31$0.25$0.13$0.07$-0.04$0.08-$-0.01$0.11$0.03
Low Forecast$1.49$1.30$1.05$0.96$1.18$1.02$0.82$0.62$0.90$0.77$0.56$0.40$0.53$0.26$0.25$0.10$0.21$0.15$0.22$0.23$0.31$0.25$0.13$0.07$-0.04$0.08-$-0.01$0.11$0.03
Surprise %-------------1.84%1.49%3.20%1.14%-0.49%-2.23%1.72%1.34%0.73%-2.75%-6.52%2.30%104.71%5.44%0.73%0.29%

According to 9 Wall Street analysts, Insulet's projected average Quarter EPS for Dec 23 is $0.65, with a low estimate of $0.53 and a high estimate of $0.79. This represents a -11.76% decrease compared to PODD previous annual EPS of $0.74 (Sep 23).

Insulet Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
TMDXTransMedics Group$65.71$116.3377.04%Buy
TNDMTandem Diabetes Care$34.23$51.4350.25%Buy
DXCMDexCom$77.80$104.5034.32%Buy
INMDInMode$17.83$21.7521.99%Hold
INSPInspire Medical Systems$190.71$223.1717.02%Buy
ALGNAlign$228.81$264.1715.45%Buy
NARIInari Medical$56.16$64.0013.96%Buy
SYKStryker$370.81$408.3310.12%Buy
ABTAbbott Laboratories$113.29$120.096.00%Buy
EWEdwards Lifesciences$74.12$76.332.98%Buy
PODDInsulet$263.35$268.001.77%Buy
IARTIntegra LifeSciences$23.03$23.00-0.13%Sell
GKOSGlaukos$146.35$144.14-1.51%Buy
MASIMasimo$174.07$168.33-3.30%Buy
PENPenumbra$247.55$230.25-6.99%Buy

PODD Forecast FAQ

Is Insulet a good buy?

Yes, according to 17 Wall Street analysts, Insulet (PODD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 15 'Buy' recommendations, accounting for 88.24% of PODD's total ratings.

What is PODD's price target?

Insulet (PODD) average price target is $268 with a range of $233 to $300, implying a 1.77% from its last price of $263.35. The data is based on 17 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Insulet stock go up soon?

According to Wall Street analysts' prediction for PODD stock, the company can go up by 1.77% (from the last price of $263.35 to the average price target of $268), up by 13.92% based on the highest stock price target, and down by -11.52% based on the lowest stock price target.

Can Insulet stock reach $400?

PODD's average twelve months analyst stock price target of $268 does not support the claim that Insulet can reach $400 in the near future.

What are Insulet's analysts' financial forecasts?

Insulet's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.43B (high $2.48B, low $2.38B), average EBITDA is $305.58M (high $311.2M, low $298.7M), average net income is $287.71M (high $303.9M, low $270.24M), average SG&A $1.04B (high $1.06B, low $1.02B), and average EPS is $3.89 (high $4.11, low $3.65). PODD's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $2.84B (high $2.89B, low $2.78B), average EBITDA is $356.83M (high $363.28M, low $348.86M), average net income is $365.92M (high $374.52M, low $355.3M), average SG&A $1.22B (high $1.24B, low $1.19B), and average EPS is $4.95 (high $5.06, low $4.8).

Did the PODD's actual financial results beat the analysts' financial forecasts?

Based on Insulet's last annual report (Dec 2022), the company's revenue was $1.31B, beating the average analysts forecast of $1.22B by 6.64%. Apple's EBITDA was $36.5M, missing the average prediction of $146.28M by -75.05%. The company's net income was $4.6M, missing the average estimation of $76.78M by -94.01%. Apple's SG&A was $587.8M, beating the average forecast of $474.78M by 23.80%. Lastly, the company's EPS was $0.07, missing the average prediction of $0.828 by -91.55%. In terms of the last quarterly report (Sep 2023), Insulet's revenue was $432.7M, beating the average analysts' forecast of $414.32M by 4.44%. The company's EBITDA was $55.5M, beating the average prediction of $52.03M by 6.67%. Insulet's net income was $51.9M, beating the average estimation of $29.8M by 74.15%. The company's SG&A was $180.7M, beating the average forecast of $177.27M by 1.94%. Lastly, the company's EPS was $0.74, beating the average prediction of $0.403 by 83.63%